Abstract
Docetaxel has been the only single active agent against chemotherapy-pretreated non-small-cell lung cancer (NSCLC). The purpose of this phase II study was to evaluate the efficacy and safety of docetaxel combined with gemcitabine, another effective drug, in patients with NSCLC previously treated with platinum-based chemotherapy. Thirty-three patients were enrolled. Prior chemotherapy was cisplatin combined with etoposide in 24 patients and vinorelbine in 9 patients. Tumors were sensitive (n=15), resistant (n=9), and refractory (n=9) to front-line chemotherapy. Treatment was docetaxel 85 mg/m2 on d 1, and gemcitabine 1200 mg/m2 on d 1 and 8, with cycles repeated every three weeks. Ten patients (30.3%, 95% CI: 15.6–48.7) achieved a partial response and 15 (45.5%) stable disease. Responses were similar frequencies in platinum-sensitive and platinum-resistant/refractory tumors. With a median follow-up period of 5.7 mo (range 1.6–20.0), the median and 6-mo event-free survival were 5.5 mo, 40.6%, respectively. Median and 6-mo over-all survival were 7.3 mo and 52.7%. Patients with progressive disease to chemotherapy (p=0.0008), higher LDH (p=0.005), and NSE levels (p=0.03) survived shorter than other patients. In patients refractory to prior chemotherapy, survival was poor as borderline significantly (p=0.06). The major hematological toxicity was neutropenia. Grade III–IV neutropenia was noted in 14 (42%) patients, with three episodes of febrile neutropenia in 111 cycles. Docetaxel combined with gemcitabine is an active and safe second-line therapy for patients with NSCLC.
Similar content being viewed by others
References
Fossella FV. Docetaxel in the treatment of non-small-lung cancer: review of single-agent trials. Semin Oncol 1999; 26(Supp 16):17–23.
Burris HA, Eckhardt J, Fields S. Phase II trials of Taxotere in patients with non-small-cell lung cancer. Proc ASCO 1993; 12:35A.
Fossella FV, et al. Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 1995; 13:645–651.
Robinet G, Kleisbauer JP, Thomas P. Phase II study of docetaxel (Taxotere) in first- and second line NSCLC. Proc ASCO 1997; 16:480A.
Gandara D, et al. Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 2000; 18:131–135.
Shepherd F, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095–2103.
Fossella FV, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previosly treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18:2354–2362.
Rosvold E, Langer CJ, Schilder R, Millenson M, Riemet E, Kreamer K. Salvage therapy with gemcitabine in advanced non-small-cell lung cancer progressing after prior carboplatin-paclitaxel. Proc. ASCO 1998; 17:467A.
Crino L, et al. Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1999; 17:2081–2085.
Baas P, Codrington H, Muller M, Dalesio O, Kwa HB, Zandwijk N. Second-line gemcitabine therapy in non-small-cell lung cancer stage IIIB and IV. Proc ASCO 2000; 18:495A.
Spiridonidis CH, et al. Second-line chemotherapy for non-small-cell lung cancer with monthly docetaxel and weekly gemcitabine: a phase II trial. Ann Oncol 2001; 12:89–94.
Kosmas C, et al. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Cancer 2001; 92:2902–2910.
Kakolyris S, et al. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study. Lung Cancer 2001; 32:179–187.
Hainsworth JD, Burris HA, III Billings FT, III Bradof JE, Baker M, Greco FA. Weekly docetaxel with either gemcitabine or vinorelbineas second-line treatment in patients with advanced nonsmall cell lung carcinoma. Cancer 2001; 92:2391–2398.
Chen YM, Perng RP, Lin WC, Wu HW, Tsai CM, Whang-Peng J. Phase II study of docetaxel and gemcitabine combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy. Am J Clin Oncol 2002; 25:509–512.
Rischin D, et al. A phase trial of docetaxel and gemcitabine in patients with advanced cancer. Ann Oncol 2000; 11:421–426.
Kosmas C, Tsavaris N, Kalofonos HP. Salvage chemotherapy with the gemcitabine/docetaxel combination in non-small cell lung cancer: an overview of recent phase II studies. Med Sci Monit 2002; 8:58–63.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tas, F., Demir, C., Camlica, H. et al. Second-line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Med Oncol 21, 233–240 (2004). https://doi.org/10.1385/MO:21:3:233
Issue Date:
DOI: https://doi.org/10.1385/MO:21:3:233